Navigation Links
Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
Date:1/4/2012

BLUE BELL, Pa., Jan. 4, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE Amex: INO), which is revolutionizing vaccines to fight cancers and infectious diseases, announced today that it has promoted Niranjan Y. Sardesai, Ph.D., from Senior Vice President Research and Development to Chief Operating Officer. In his expanded role, Dr. Sardesai will be responsible for corporate and business development for the company in addition to continuing to oversee research and development. Inovio also announced the retirement of Kevin W. Rassas, former Senior Vice President Business Development.

Dr. J. Joseph Kim, President and CEO of Inovio Pharmaceuticals, said, "Niranjan brings to the COO position a strong combination of strategic business, transactional, and technical skills and broad operating experience. He has overseen the integration, development, and growth of Inovio's pipeline through the advancement of its proprietary technology as well as licensing and M&A efforts. We are pleased to have him assume this broader responsibility to help guide and execute Inovio's business plan to develop important new vaccines. Kevin played a vital role in the formative years of our predecessor company, VGX Pharmaceuticals, bringing big Pharma management experience to an entrepreneurial environment, and subsequently in advancing Inovio's key business relationships. We thank him for his contribution and commitment to Inovio and wish him the very best in the future."

Dr. Sardesai has broad operating and consulting experience in biotechnology and pharmaceuticals. He joined VGX Pharmaceuticals as VP Research and Development in 2006, was promoted to SVP R&D in 2007 and, with the merger of VGX with Inovio in June 2009, became SVP Research & Development of the merged company. Dr. Sardesai is responsible for leading the company's product development programs in infectious disease and cancer vaccines and vaccine delivery systems. He has secured ov
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inovio Pharmaceuticals DNA Vaccine for Foot-and-Mouth Disease Generates Protective Neutralizing Antibodies in Second Large-Animal Study
2. Inovio Pharmaceuticals Prostate Cancer DNA Vaccine Demonstrates Strong T Cell Responses in Monkeys; Company on Track for Phase I Clinical Trial
3. Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
4. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
5. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
6. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
7. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
11. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Neuraltus Pharmaceuticals, Inc. , a ... groundbreaking drugs to treat neurodegenerative diseases such as ... Robert G. Miller , M.D., Director of the Forbes ... Pacific Medical Center in San Francisco, has been awarded ... million to help fund a Phase 2 clinical ...
(Date:7/1/2015)... (PRWEB) , ... July 01, 2015 , ... Apex Therapeutics ... BIO International Convention in Philadelphia, PA. , The presentation took place on ... outlined the plans for the development of APX3330 for the treatment of pancreatic cancer. ...
(Date:6/30/2015)... , June 30, 2015 /PRNewswire/ - Resverlogix ... of common shares of Resverlogix have approved the ... Eastern Capital Limited of 5,600,000 units at a ... Placement"), each unit being comprised of one common ... aggregate proceeds of approximately CAD$15 million; and (ii) ...
(Date:6/30/2015)... ... June 30, 2015 , ... uBiome and OpenBiome Partner for ... of fecal microbiota transplantation in C. difficile patients. , SAN FRANCISCO, uBiome and ... fecal microbiota transplantation (FMT) as a treatment for Clostridium difficile infections (C. diff). ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 2uBiome and OpenBiome Partner for Microbiome Study in FMT Patients 3
... Germany - A "sister park" agreement has been ... and the Frankfurt Biotechnology Innovation Center in Frankfurt, one ... understanding between the two research parks was signed in ... Director Mark Bugher and Christian Garbe, managing director of ...
... cords, and can the cables as we move deeper into ... freedom and mobility, we are nowhere without energy to power ... fact alone has turned the average business traveler into a ... of airports and coffee houses. Indeed, Im usually the last ...
... -- Careers in manufacturing are high-wage and high-tech. Yet, ... It appears a negative public perception - one that ... - is thwarting young adults from pursuing manufacturing careers ... 10 million new skilled workers by 2020, according to ...
Cached Biology Technology:Power for the people 2State campaign seeks to reverse negative perception of manufacturing work 2State campaign seeks to reverse negative perception of manufacturing work 3State campaign seeks to reverse negative perception of manufacturing work 4State campaign seeks to reverse negative perception of manufacturing work 5
(Date:6/24/2015)... 2015  Synaptics Inc. (NASDAQ: SYNA ), ... announced that Sharp has selected its industry-leading Natural ... its latest flagship smartphone device, the AQUOS ZETA ... shipments of its fingerprint ID sensor technology, this ... and leadership in the biometrics market through its ...
(Date:6/23/2015)... June 23, 2015   Valencell, a ... results of a recent study that illustrates its ... wrist during activity. In a study conducted at ... along with the Apple Watch against a chest ... rate during activity. The study demonstrated that Valencell,s ...
(Date:6/17/2015)... Maryland , and HILDEN, Germany , ... QGEN ; Frankfurt Prime Standard: QIA) today launched new ... evidence in forensic laboratories in the United States ... solution to simultaneously analyze multiple key genomic markers (short tandem ... ® Quality Sensor to evaluate the quality of DNA ...
Breaking Biology News(10 mins):Synaptics Brings Natural ID Technology to Sharp's Newest Flagship Smartphone 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 2Valencell Delivers Breakthrough Heart Rate Accuracy on the Wrist 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5
... York University School of Medicine report in a new study ... the production of myelin, the fatty insulation around nerve cells ... The study, published in the September 1, 2005, issue of ... nervous system diseases such as multiple sclerosis, which are associated ...
... the Gulf states and Guatemala have raised the risks ... identified a new type of antibiotic against the cholera ... with processes essential for their survival, the new agent ... diarrhea associated with Vibrio cholerae infection. , "What ...
... research from the University of Sheffield has shown that major ... greater impact on populations of British sea birds than was ... Birkhead from the Department of Animal and Plant Sciences at ... major oil spills double the mortality rate of adult guillemots ...
Cached Biology News:Scientists discover the molecular switch for nerve cells' insulating jelly rolls 2Oil spills and climate change double the mortality rate of British seabirds 2
... Inhibitor (patent pending) is a protein based ... and inhibits the most common and troublesome ... and T1. SUPERaseIn can be used in ... problematic. It is ideal for in vitro ...
... Printer) is a revolutionary new approach ... Macroarray Analysis, developed in conjunction with ... compliments established protocols in resolving proteins ... isoelectric point and apparent molecular weight). ...
...
... corresponding to the third cytoplasmic loop of ... to KLH. The immunizing peptide has 79% ... Physical form: Solution in phosphate buffered ... Titertest method: IHC (p). Titertest ...
Biology Products: